Drug Database
Back to search

Poland· PL-100306753

Invokana

A canagliflozin product containing canagliflozinum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 15 of our 19 countries.

ATC A10BK02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedInvokanaATCA10BK02REGISTER NO.PL-100306753PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about canagliflozinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Canagliflozin is registered in 15 of 19 countries.

Countries holding a registration under ATC A10BK02 (canagliflozin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search canagliflozin products by name

Canagliflozin · ATC A10BK02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of canagliflozin costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $2.52 in Switzerland to $25.50 in United States — a ×10 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Canagliflozin · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • US United States$25.50 (acquisition cost)
  • IT Italy$3.76
  • CH Switzerland$2.52
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Canagliflozinum
Manufacturer
Janssen-Cilag International N.V.
Country
Poland (PL)
ATC code
A10BK02
ATC class
Canagliflozin
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

1 priced
  • gtin
    05909991096144
  • gtin
    05909991096090
  • gtin
    05909991096106
    30 szt.
    PLN 154.89
  • gtin
    05909991096137

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

429 interactions on record for canagliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check canagliflozin against other medicinesHow interaction checks work

Canagliflozin · interactions on record

429 records

  • 1 severe
  • 388 moderate
  • 40 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • PapaverineA03AD01moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Canagliflozin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Invokana
  • Liechtenstein · Invokana
  • Norway · Invokana

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a288f565-d1c6-4ba2-83e5-441287dd593e
GET /v1/drugs/a288f565-d1c6-4ba2-83e5-441287dd593e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05909991096090 ¦ Rp ¦ EU/1/13/884/001 ¦ 87618\n10 tabl.\n05909991096106 ¦ Rp ¦ EU/1/13/884/002 ¦ 87619\n30 tabl.\n05909991096137 ¦ Rp ¦ EU/1/13/884/003 ¦ 87620\n90 tabl.\n05909991096144 ¦ Rp ¦ EU/1/13/884/004 ¦ 87621\n100 tabl.",
  "substance": "Canagliflozinum 100 mg",
  "common_name": "Canagliflozinum",
  "pl_product_id": "100306753",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about canagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console